Skye Bioscience (SKYE)
(Delayed Data from NSDQ)
$3.79 USD
+0.16 (4.41%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.80 +0.01 (0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Skye Bioscience, Inc. has a market cap of $117.39M, which represents its share price of $3.79 multiplied by its outstanding shares number of 30.98M. As a small-cap company, SKYE's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SKYE 3.79 +0.16(4.41%)
Will SKYE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SKYE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SKYE
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
SKYE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SKYE
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August ...
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
JMP Securities Reiterates Market Outperform Rating for Skye Bioscience (SKYE) | SKYE Stock News
Citizens JMP Sticks to Their Buy Rating for Skye Bioscience (SKYE)
Skye (SKYE) Explores Nimacimab's Role in Obesity Treatment at Evercore Event | SKYE Stock News